Roche Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ROCHE
ROCHE has sixty-one approved drugs.
Summary for Roche
| US Patents: | 0 |
| Tradenames: | 49 |
| Ingredients: | 45 |
| NDAs: | 61 |
Drugs and US Patents for Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | TARACTAN | chlorprothixene | TABLET;ORAL | 012486-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Roche | KYTRIL | granisetron hydrochloride | INJECTABLE;INJECTION | 020239-003 | Sep 17, 2004 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Roche | NIPRIDE | sodium nitroprusside | INJECTABLE;INJECTION | 017546-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Roche | GANTANOL | sulfamethoxazole | TABLET;ORAL | 012715-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Roche | DEMADEX | torsemide | SOLUTION;INTRAVENOUS | 020137-001 | Aug 23, 1993 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Roche | SYNKAYVITE | menadiol sodium diphosphate | TABLET;ORAL | 003718-010 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Roche | KYTRIL | granisetron hydrochloride | INJECTABLE;INJECTION | 020239-004 | Mar 11, 1994 | 6,294,548 | ⤷ Start Trial |
| Roche | HIVID | zalcitabine | TABLET;ORAL | 020199-002 | Jun 19, 1992 | 5,028,595 | ⤷ Start Trial |
| Roche | MENRIUM 10-4 | chlordiazepoxide; estrogens, esterified | TABLET;ORAL | 014740-006 | Approved Prior to Jan 1, 1982 | 4,316,897 | ⤷ Start Trial |
| Roche | HIVID | zalcitabine | TABLET;ORAL | 020199-001 | Jun 19, 1992 | 5,028,595 | ⤷ Start Trial |
| Roche Palo | CELLCEPT | mycophenolate mofetil hydrochloride | INJECTABLE;INJECTION | 050758-001 | Aug 12, 1998 | 4,753,935 | ⤷ Start Trial |
| Roche Palo | CELLCEPT | mycophenolate mofetil | TABLET;ORAL | 050723-001 | Jun 19, 1997 | 4,753,935 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ROCHE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 0.1 mg/mL, 1 mL single dose vial | ➤ Subscribe | 2007-03-08 |
| ➤ Subscribe | Injection | 1 mg/mL, 4 mL multi-dose vials | ➤ Subscribe | 2004-07-19 |
| ➤ Subscribe | Tablets | 2.5 mg and 150 mg | ➤ Subscribe | 2007-05-16 |
| ➤ Subscribe | Capsule | 75 mg | ➤ Subscribe | 2010-11-15 |
| ➤ Subscribe | Oral Suspension | 6 mg/mL | ➤ Subscribe | 2015-06-18 |
| ➤ Subscribe | Injection | 1 mg/mL, 1 mL vials | ➤ Subscribe | 2004-06-01 |
| ➤ Subscribe | Injection | 1 mg/mL, 3 mL Vial | ➤ Subscribe | 2007-08-31 |
| ➤ Subscribe | For Oral Suspension | 200 mg/mL | ➤ Subscribe | 2011-03-25 |
| ➤ Subscribe | Capsules | 30 mg and 45 mg | ➤ Subscribe | 2011-08-02 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
